Serina Therapeutics, Inc. (SER) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$3.3M

EPS$-1.60

Market Cap$24.9M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Steven Ledger

CEO & Executive Director

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinsonâs disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinsonâs and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Founded: 2017
Employees: 13
Headquarters

⚡

Core Efficiency

ROE?

9016.22%

ROA?

-47.99%

D/E Ratio?

-188.86

📊

Profitability Ratios

Current Ratio?

1.71

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 17, 2026 (in 130 days)

Annual Report (10-K) — Based on filing pattern

Aug 17, 2026

Predicted10-K

Mar 27, 2026

10-K/AQ4 20259d after period end

Nov 13, 2025

10-QQ3 20253d after period end

Aug 11, 2025

10-QQ2 20253d after period end

May 8, 2025

10-QQ1 20252d after period end

Mar 24, 2025

10-KQ4 20244d after period end

Nov 12, 2024

10-QQ3 20245d after period end

Aug 9, 2024

10-QQ2 20244d after period end

May 14, 2024

10-QQ1 20245d after period end

Loading company sections...

Serina Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness